Impact of 5-aminosalicylic acid on ustekinumab in inflammatory bowel disease: A retrospective medical claims analysis

The efficacy of 5-aminosalicylic acid (5-ASA) in combination with advanced therapies, particularly ustekinumab (UST), for the treatment of inflammatory bowel disease (IBD) remains unclear.

This retrospective cohort analysis used data from the Medical Data Vision database, including patients with ulcerative colitis (UC) and Crohn’s disease (CD) who had initiated UST therapy. Cumulative UST continuation rates and factors associated with UST failure were analyzed, and post hoc subgroup analyses based on prior advanced therapies use were conducted.

A total of 1,971 patients with CD and 1,284 patients with UC were included. Overall, the concomitant use of 5-ASA did not significantly affect UST failure in either CD or UC. Post hoc subgroup analysis suggested a protective effect of 5-ASA in advanced therapies-naïve patients with CD or UC who had been previously exposed to advanced therapies.

5-ASA did not provide a significant overall benefit when used in combination with UST for CD or UC. However, post hoc subgroup analyses indicated a potential role for 5-ASA in specific subgroups. Further studies are necessary to confirm these findings and explore personalized treatment strategies.

###

About OMU

Established in Osaka as one of the largest public universities in Japan, Osaka Metropolitan University is committed to shaping the future of society through “Convergence of Knowledge” and the promotion of world-class research. For more research news, visit https://www.omu.ac.jp/en/ and follow us on social media: X, Facebook, Instagram, LinkedIn.